Oxaliplatin Eugia

Oxaliplatin, the active ingredient in Oxaliplatin Eugia, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of colorectal cancer, typically administered to adult patients undergoing combination chemotherapy regimens.

GNH USA supplies Oxaliplatin Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Eugia is used primarily for colorectal cancer treatment, acting on the cellular pathways that drive tumor growth. - Colorectal cancer: Enhances tumor response when combined with fluoropyrimidine‑based regimens. - Gastric cancer: Used in combination protocols for advanced disease. - Pancreatic cancer: Contributes to disease control within multi‑drug regimens.

Adverse reactions to Oxaliplatin Eugia vary in frequency and severity.

Common Side Effects: - Peripheral neuropathy: Tingling or numbness, often dose‑related. - Nausea and vomiting: May require anti‑emetic prophylaxis. - Diarrhea: Can be mild to moderate. - Fatigue: Generalised tiredness during treatment cycles. - Myelosuppression: Reduced white blood cells, platelets or red cells.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Including anaphylaxis. - Acute neurotoxicity: Sudden onset of severe paresthesia. - Hemolytic anemia: Autoimmune‑mediated red cell destruction. - Cardiac arrhythmias: Uncommon but reported in susceptible patients. - Pulmonary toxicity: Interstitial lung disease or pneumonitis.

When handling Oxaliplatin Eugia, clinicians should observe specific safety measures to minimise risks to patients and staff. - Renal function monitoring: Assess creatinine clearance before each cycle. - Hepatic function monitoring: Check liver enzymes regularly. - Pre‑hydration: Provide adequate intravenous fluids to reduce nephrotoxicity. - Neuropathy assessment: Evaluate sensory changes before each dose. - Avoid concurrent neurotoxic agents: Reduce cumulative nerve damage risk. - Store at below 25°C: Keep in the original container, protect from light and moisture.

Oxaliplatin Eugia may interact with several concomitant medicines; awareness of interaction severity guides clinical management.

Major Interactions (Avoid): - Aminoglycoside antibiotics: Heightened risk of ototoxicity. - High‑dose vitamin C: May diminish platinum‑DNA binding efficacy.

Moderate Interactions (Monitor Closely): - Antiemetic 5‑HT3 antagonists: May alter plasma concentrations. - Loop diuretics: Potentially increase nephrotoxic risk. - Anticoagulants: Enhanced bleeding tendency during thrombocytopenia. - NSAIDs: May aggravate renal impairment. - CYP enzyme inducers: Could affect drug clearance indirectly.